Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in Pediatric Ulcerative Colitis
2023-507142-83-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of golimumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission by Mayo score. Started Jul 2024; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-507142-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507142-83-00.